Ocrelizumab alters the circulating metabolome in people with relapsing-remitting multiple sclerosis.

ABSTRACT:

Background

Circulating metabolite levels are altered in multiple sclerosis (MS) and are associated with MS severity. However, how metabolic profiles shift following highly efficacious therapies, like ocrelizumab remains unclear.

Objective

Circulating metabolite levels are altered in multiple sclerosis (MS) and are associated with MS severity. However, how metabolic profiles shift following highly efficacious therapies, like ocrelizumab remains unclear. To assess changes in the circulating metabolome produced by ocrelizumab treatment in people with relapsing-remitting MS (RRMS).

Methods

Thirty-one individuals with RRMS eligible for beginning treatment with ocrelizumab were recruited and followed with demographic, clinical, quality-of-life, and global metabolomics data

SUBMITTER: Siavoshi F 

PROVIDER: S-EPMC11537130 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature